Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Gibson Dan


 Last updated December 2021 - School of Pharmacy

List of Publications

(1) Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, et al. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? J Med Chem 2021;64(15):11364-11378.

(2) Gibson D. Pt(IV) Anticancer Prodrugs – A Tale of Mice and Men. ChemMedChem 2021;16(14):2188-2191.

(3) Gibson D. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end? J Inorg Biochem 2021;217.

(4) Karmakar S, Kostrhunova H, Ctvrtlikova T, Novohradsky V, Gibson D, Brabec V. Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells. J Med Chem 2020;63(22):13861-13877.

(5) Khattib D, Ishan M, Karmakar S, Kostrhunova H, Brabec V, Gibson D. Oxidation of cis-Diamminediacetato PtII with Hydrogen Peroxide Can Give Rise to Two Isomeric PtIV Products. Chem Eur J 2020;26(43):9475-9480.

(6) Chen CKJ, Kappen P, Gibson D, Hambley TW. trans-Platinum(iv) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells:1H NMR and XANES spectroscopy study. Dalton Trans 2020;49(23):7722-7736.

(7) Karges J, Yempala T, Tharaud M, Gibson D, Gasser G. A Multi-action and Multi-target RuII–PtIV Conjugate Combining Cancer-Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers. Angew Chem Int Ed 2020;59(18):7069-7075.

(8) Babu T, Sarkar A, Karmakar S, Schmidt C, Gibson D. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. Inorg Chem 2020;59(7):5182-5193.

(9) Yempala T, Babu T, Gibson D, Cassels BK. Dibenzofuran annulated 1-azepines: Synthesis and cytotoxicity. Synth Commun 2020;50(3):438-445.

(10) Karmakar S, Poetsch I, Kowol CR, Heffeter P, Gibson D. Synthesis and Cytotoxicity of Water-Soluble Dual- A nd Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. Inorg Chem 2019;58(24):16676-16688.

(11) Yempala T, Babu T, Karmakar S, Nemirovski A, Ishan M, Gandin V, et al. Expanding the Arsenal of PtIV Anticancer Agents: Multi-action PtIV Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angew Chem Int Ed 2019;58(50):18218-18223.

(12) Babak MV, Zhi Y, Czarny B, Toh TB, Hooi L, Chow EK-, et al. Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity. Angew Chem Int Ed 2019;58(24):8109-8114.

(13) Kostrhunova H, Zajac J, Novohradsky V, Kasparkova J, Malina J, Aldrich-Wright JR, et al. A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. J Med Chem 2019;62(10):5176-5190.

(14) Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V. An Anticancer Pt IV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects. Chem Eur J 2019;25(20):5235-5245.

(15) Gibson D. Multi-action Pt(IV) anticancer agents; do we understand how they work? J Inorg Biochem 2019;191:77-84.

(16) Petruzzella E, Sirota R, Solazzo I, Gandin V, Gibson D. Triple action Pt(iv) derivatives of cisplatin: A new class of potent anticancer agents that overcome resistance. Chem Sci 2018;9(18):4299-4307.

(17) Novohradsky V, Zanellato I, Marzano C, Pracharova J, Kasparkova J, Gibson D, et al. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates. Sci Rep 2017;7(1).

(18) Petruzzella E, Braude JP, Aldrich-Wright JR, Gandin V, Gibson D. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angew Chem Int Ed 2017;56(38):11539-11544.

(19) Harper BWJ, Friedman-Ezra A, Sirota R, Petruzzella E, Aldrich-Wright JR, Gibson D. Probing the Interactions of Cytotoxic [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)] and Its PtIV Derivatives with Human Serum. ChemMedChem 2017;12(7):510-519.

(20) Sirota R, Gibson D, Kohen R. The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines. Redox Biol 2017;11:170-175.

(21) Harper BWJ, Petruzzella E, Sirota R, Faccioli FF, Aldrich-Wright JR, Gandin V, et al. Synthesis, characterization and: In vitro and in vIVo anticancer actIVity of Pt(IV) derIVatIVes of [Pt(1 S,2 S -DACH)(5,6-dimethyl-1,10-phenanthroline)]. Dalton Trans 2017;46(21):7005-7019.

(22) Abu Ammar A, Raveendran R, Gibson D, Nassar T, Benita S. A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity. J Med Chem 2016;59(19):9035-9046.

(23) Raveendran R, Braude JP, Wexselblatt E, Novohradsky V, Stuchlikova O, Brabec V, et al. Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chem Sci 2016;7(3):2381-2391.

(24) Zajac J, Kostrhunova H, Novohradsky V, Vrana O, Raveendran R, Gibson D, et al. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin. J Inorg Biochem 2016;156:89-97.

(25) Gibson D. Platinum(IV) anticancer prodrugs-hypotheses and facts. Dalton Trans 2016;45(33):12983-12991.

(26) Novohradsky V, Zerzankova L, Stepankova J, Vrana O, Raveendran R, Gibson D, et al. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells. Biochem Pharmacol 2015;95(3):133-144.

(27) Sirota R, Gibson D, Kohen R. The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/Keap1 pathway activation in ovarian carcinoma cell lines. Redox Biol 2015;4:48-59.

(28) Brabec V, Pracharova J, Novakova O, Gibson D, Kasparkova J. The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions. Dalton Trans 2015;44(8):3573-3582.

(29) Wexselblatt E, Raveendran R, Salameh S, Friedman-Ezra A, Yavin E, Gibson D. On the stability of PtIV pro-drugs with haloacetato ligands in the axial positions. Chem Eur J 2015;21(7):3108-3114.

(30) Li J, Pant A, Chin CF, Ang WH, Ménard-Moyon C, Nayak TR, et al. In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes. Nanomed Nanotechnol Biol Med 2014;10(7):1465-1475.

(31) Novohradsky V, Zerzankova L, Stepankova J, Vrana O, Raveendran R, Gibson D, et al. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. J Inorg Biochem 2014;140:72-79.

(32) Zivi E, Barash D, Aizenman E, Gibson D, Shufaro Y. Zygote serine decreased uptake from the fertilization medium is associated with implantation and pregnancy. J Assisted Reprod Genet 2014;31(7):889-897.

(33) Wexselblatt E, Yavin E, Gibson D. Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions. Angew Chem Int Ed 2013;52(23):6059-6062.

(34) Prachařová J, Nováková O, Kašpárková J, Gibson D, Brabec V. Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-PtII complexes containing long alkane linkers. Pure Appl Chem 2013;85(2):343-354.

(35) Zhang JZ, Bonnitcha P, Wexselblatt E, Klein AV, Najajreh Y, Gibson D, et al. Facile preparation of mono-, Di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design. Chem Eur J 2013;19(5):1672-1676.

(36) Frybortova M, Novakova O, Stepankova J, Novohradsky V, Gibson D, Kasparkova J, et al. Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. J Inorg Biochem 2013;126:46-54.

(37) Zhang JZ, Wexselblatt E, Hambley TW, Gibson D. Pt(iv) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. Chem Commun 2012;48(6):847-849.

(38) Wexselblatt E, Gibson D. What do we know about the reduction of Pt(IV) pro-drugs? J Inorg Biochem 2012;117:220-229.

(39) Wexselblatt E, Yavin E, Gibson D. Cellular interactions of platinum drugs. Inorg Chim Acta 2012;393:75-83.

(40) Kostrhunova H, Kasparkova J, Gibson D, Brabec V. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione. Mol Pharm 2010;7(6):2093-2102.

(41) Kostrhunova H, Vrana O, Suchankova T, Gibson D, Kasparkova J, Brabec V. Different features of the DNA binding mode of antitumor cis -amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro. Chem Res Toxicol 2010;23(11):1833-1842.

(42) Nemirovski A, Vinograd I, Takrouri K, Mijovilovich A, Rompel A, Gibson D. New reduction pathways for ctc-[PtCl2(CH3CO 2)2(NH3)(Am)] anticancer prodrugs. Chem Commun 2010;46(11):1842-1844.

(43) Gibson D. The mechanism of action of platinum anticancer agents - What do we really know about it? Dalton Trans 2009(48):10681-10689.

(44) Kasherman Y, Sturup S, Gibson D. Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts. J Med Chem 2009;52(14):4319-4328.

(45) Kasherman Y, Sturup S, Gibson D. Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts. J Biol Inorg Chem 2009;14(3):387-399.

(46) Gabbiani C, Casini A, Mastrobuoni G, Kirshenbaum N, Moshel O, Pieraccini G, et al. Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. J Biol Inorg Chem 2008;13(5):755-764.

(47) Halámiková A, Heringová P, Kašpárková J, Intini FP, Natile G, Nemirovski A, et al. Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine. J Inorg Biochem 2008;102(5-6):1077-1089.

(48) Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. J Pain 2008;9(3):254-264.

(49) Nemirovski A, Kasherman Y, Tzaraf Y, Gibson D. Reduction of cis,trans,cis-[PtCl2(OCOCH3) 2(NH3)2] by aqueous extracts of cancer cells. J Med Chem 2007;50(23):5554-5556.

(50) Brabec V, Christofis P, Slámová M, Kostrhunová H, Nováková O, Najajreh Y, et al. DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)]. Biochem Pharmacol 2007;73(12):1887-1900.

(51) Najajreh Y, Khazanov E, Jawbry S, Ardeli-Tzaraf Y, Perez JM, Kasparkova J, et al. Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies. J Med Chem 2006;49(15):4665-4673.

(52) Najajreh Y, Ardeli-Tzaraf Y, Kasparkova J, Heringova P, Prilutski D, Balter L, et al. Interactions of platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with biological nucleophiles. J Med Chem 2006;49(15):4674-4683.

(53) Anzellotti A, Stefan S, Gibson D, Farrell N. Donor atom preferences in substitution reactions of trans-platinum mononucleobase compounds: Implications for DNA-protein selectivity. Inorg Chim Acta 2006;359(9):3014-3019.

(54) Gibson D, Kasherman Y, Kowarski D, Freikman I. The trans labilization of cis-[PtCl2(13CH 3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR. J Biol Inorg Chem 2006;11(2):179-188.

(55) Balter L, Gibson D. Mass spectrometric studies of the formation and reactivity of trans-[PtCl2(Am)(piperidinopiperidine)]·HCl complexes with ubiquitin. Rapid Commun Mass Spectrom 2005;19(24):3666-3672.

(56) Najajreh Y, Kasparkova J, Marini V, Gibson D, Brabec V. Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand. J Biol Inorg Chem 2005;10(7):722-731.

(57) Jawbry S, Freikman I, Najajreh Y, Perez JM, Gibson D. Preparation, cytotoxicity and interactions with nucleophiles of three isomeric transplatinum complexes containing methylpiperidine ligands. J Inorg Biochem 2005;99(10):1983-1991.

(58) Sobol E, Yagen B, Winkler I, Britzi M, Gibson D, Bialer M. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metab Dispos 2005;33(10):1538-1546.

(59) Najajreh Y, Prilutski D, Ardeli-Tzaraf Y, Perez JM, Khazanov E, Barenholz Y, et al. Structure and unique interactions with DNA of a cationic Trans-platinum complex with the nonplanar bicyclic piperidinopiperidine ligand. Angew Chem Int Ed 2005;44(19):2885-2887.

(60) Aronov O, Horowitz AT, Gabizon A, Fuertes MA, Pérez JM, Gibson D. Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues. Bioconjugate Chem 2004;15(4):814-823.

(61) Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 2004;47(15):3800-3806.

(62) Kasparkova J, Novakova O, Marini V, Najajreh Y, Gibson D, Perez J-, et al. Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand. Mechanistic studies on antitumor action. J Biol Chem 2003;278(48):47516-47525.

(63) Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez J-, Brabec V. Effects of a Piperidine Ligand on DNA Modification by Antitumor Cisplatin Analogues. Chem Res Toxicol 2003;16(11):1424-1432.

(64) Kasparkova J, Marini V, Najajreh Y, Gibson D, Brabec V. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry 2003;42(20):6321-6332.

(65) Aronov O, Horowitz AT, Gabizon A, Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjugate Chem 2003;14(3):563-574.

(66) Najajreh Y, Peleg-Shulman T, Moshel O, Farrel N, Gibson D. Ligand effects on the binding of cis- and trans-[PtCl2Am1Am2 to proteins. J Biol Inorg Chem 2003;8(1-2):167-175.

(67) Najajreh Y, Perez JM, Navarro-Ranninger C, Gibson D. Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J Med Chem 2002;45(24):5189-5195.

(68) Khazanov E, Barenholz Y, Gibson D, Najajreh Y. Novel apoptosis-inducing trans-platinum piperidine derivatives: Synthesis and biological characterization. J Med Chem 2002;45(24):5196-5204.

(69) Peleg-Shulman T, Najajreh Y, Gibson D. Interactions of cisplatin and transplatin with proteins.Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J Inorg Biochem 2002;91(1):306-311.

(70) Gibson D. Drug-DNA interactions and novel drug design. Pharmacogenomics J 2002;2(5):275-276.

(71) Peleg-Shulman T, Gibson D. Cisplatin-protein adducts are efficiently removed by glutathione but not by 5′-guanosine monophosphate. J Am Chem Soc 2001;123(13):3171-3172.

(72) Peleg-Shulman T, Gibson D, Cohen R, Abra R, Barenholz Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim Biophys Acta Biomembr 2001;1510(1-2):278-291.

(73) Peleg-Shulman T, Katzhendler J, Gibson D. Effects of monofunctional platinum binding on the thermal stability and conformation of a self-complementary 22-mer. J Inorg Biochem 2000;81(4):313-323.

(74) Gibson D, Costello CE. Mass spectrometry of biomolecules. Sep Sci Technol 2000;2(C):299-327.

(75) Gibson D, Costello CE. A mass spectral study of the binding of the anticancer drug cisplatin to ubiquitin. Eur J Mass Spectrom 1999;5(6):501-510.

(76) Bauer C, Peleg-Shulman T, Gibson D, Wang AH-. Monofunctional platinum amine complexes destabilize DNA significantly. Eur J Biochem 1998;256(2):253-260.

(77) Ferreira ADQ, Bino A, Gibson D. Preparation, Structure and Stability of cis-{Cr(phen)2[OP(O)(OC6H5)2](H 2O)}2+ as a Model for Cr(III)-DNA Adducts. Inorg Chem 1998;37(26):6560-6561.

(78) Ferreira ADQ, Bino A, Gibson D. Novel carboplatin analogs containing flexible and potentially intercalating ligands: Preparation and X-ray crystal structures of di-2-pyridyl ketone cyclobutanedicarboxylate platinum(II) and of 2,3-bis(2-pyridyl)pyrazine cyclobutane dicarboxylate platinum(II). Inorg Chim Acta 1997;265(1-2 PART II):155-161.

(79) Gibson D, Binyamin I, Haj M, Ringel I, Ramu A, Katzhendler J. Anthraquinone intercalators as carrier molecules for second-generation platinum anticancer drugs. Eur J Med Chem 1997;32(10):823-831.

(80) Breuer E, Zaher H, Tashma Z, Gibson D. Acylphosphonamidates and α-hydroxyiminophosphonamidates. Synthesis of N-acylphosphordiamidates by Beckmann rearrangement. Crystal structure of (E)-α-hydroxyiminobenzyl-1-pyrrolidinylphosphinate. Heteroatom Chem 1996;7(6):515-520.

(81) Gibson D, Mansur N, Gean KF. Preparation, characterization, and antitumor properties of cis-PtCl2 complexes linked to anthraquinones through position number 2. J Inorg Biochem 1995;58(2):79-88.

(82) Doungdee P, Sarel S, Ringel I, Gibson D, Wongvisetsirikul N, Avramovici-Grisaru S. Iron chelators of the pyridoxal 2-pyridyl hydrazone class. part III.1 Ionisation and conformational characteristics of the ligands. Heterocycles 1995;40(1):241-248.

(83) Arvanitis GM, Gibson D, Emge TJ, Berman HM. Platinum(II) triamine complexes: cis-[PtCl(NH3)2(C10H13N5O5)]NO3.2H2O and [PtCl(C2H8N2)(C4H6N2)]NO3. Acta Crystallogr C 1994;50 ( Pt 8):1217-1220.

(84) Gibson D, Arvanitis GM, Berman HM. Ternary Pt(II)-amino acid-nucleotide complexes: kinetics of formation. Inorg Chim Acta 1994;218(1-2):11-19.

(85) Rosenfeld A, Blum J, Gibson D, Ramu A. Preparation, characterization and antileukemic properties of diaminemalonatoplatinum(II) complexes tethered to ferrocene. Inorg Chim Acta 1992;201(2):219-221.

(86) Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-1949.

(87) Breuer E, Safadi M, Chorev M, Gibson D. Evaluation of the n-phthaloyl moiety as protecting group in aminoacylphosphonic derivatives. Phosphorus Sulfur Silicon Relat Elem 1991;60(3-4):239-246.

(88) Gibson D, Gean K-, Ben-Shoshan R, Katzhendler J, Ramu A, Ringel I. Preparation, Characterization, and Anticancer Activity of a Series of cis-PtCl2 Complexes Linked to Anthraquinone Intercalators. J Med Chem 1991;34(1):414-420.

(89) Gean K, Ben-Shoshan R, Ramu A, Ringel I, Katzhendler J, Gibson D. Preparation, characterization and the anticancer activity of a novel series of triaminemonochloroplatinum(II) cations linked to anthraquinone intercalators. Eur J Med Chem 1991;26(6):593-598.

(90) Schlossman A, Gibson D, Breuer E. Rearrangement and fragmentation reactions of α-hydroxyiminophoshinates. On the nature of the metaphosphonate intermediate involved in phosphonylations by α-hydroxyiminophosphinate. Phosphorus Sulfur Silicon Relat Elem 1990;49-50(1-4):81-84.

(91) Breuer E, Schlossman A, Safadi M, Gibson D, Chorev M, Leader H. Stereoselectivity in fragmentation and rearrangement of α-hydroxyimino-phosphinates and -phosphonates. A synthetic approach to acylphosphon- and phosphor-amidates. Crystal structures of methyl (E)-α-hydroxyimino-benzylphenylphosphinate and methyl benzoylphenylphosphonamidate. Journal of the Chemical Society, Perkin Transactions 1 1990(12):3263-3269.

(92) Gibson D, Rosenfeld A, Apfelbaum H, Blum J. Multinuclear (195Pt, 15N, 13C) NMR studies of the reactions between cis-diaminediaquaplatinum(ii) complexes and aminomalonate. Inorg Chem 1990;29(25):5125-5129.

(93) Breuer E, Safadi M, Chorev M, Gibson D. Novel Amino Acid Derivatives. Preparation and Properties of Aminoacylphosphonates and Amino Hydroxyimino Phosphonates. J Org Chem 1990;55(25):6147-6153.

(94) Coll M, Sherman SE, Gibson D, Lippard SJ, Wang AH-. Molecular structure of the complex formed between the anticancer drug cisplatin and d(PGpG): C2221 crystal form. J Biomol Struct Dyn 1990;8(2):315-330.

(95) Breuer E, Karaman R, Goldblum A, Gibson D, Leader H, Potter BVL, et al. Erratum: α-Oxyiminophosphonates: Chemical and physical properties. Reactions, theoretical calculations and crystal structures of (E)- And (Z)-dimethyl α-Hydroxyiminobenzylphosphonates (Journal of the Chemical Society, Perkin Transactions 1 (1988) 3047). Journal of the Chemical Society, Perkin Transactions 1 1989(7):1367.

(96) Katzhendler J, Ringel I, Goldblum A, Gibson D, Tashma Z. Conformational studies of substituted five-membered cyclic carbonates and related compounds by MNDO, and the X-ray crystal structure of 4-chlorophenyloxymethyl-1,3-dioxolan-2-one. Journal of the Chemical Society, Perkin Transactions 2 1989(11):1729-1739.

(97) Breuer E, Karaman R, Gibson D, Goldblum A. Structure and reactivity of 2-hydroxyiminobenzyl-2-oxo-4,4,5,5-tetramethyl[1,3,2]dioxaphospholanes. Phosphorus Sulfur Silicon Relat Elem 1989;41(3-4):433-437.

(98) Gibson D, Karaman R. Metal complexes of α-hydroxyiminophosphonic acid derivatives. Preparation and crystal structures of calcium and cadmium complexes of methyl (E)-α-hydroxyiminobenzylphosphonate. Journal of the Chemical Society, Dalton Transactions 1989(10):1911-1914.

(99) Katzhendler J, Karaman R, Gibson D, Breuer E, Leader H. Fragmentation of methyl hydrogen α-hydroxyiminophosphonates to monomeric methyl metaphosphate: Stereochemistry and mechanism. Journal of the Chemical Society, Perkin Transactions 2 1989(6):589-594.

(100) Gibson D, Karaman R. Metal complexes of α-hydroxyimino phosphonic acid derivatives. Separation of the E and Z isomers by metal chelation and the preparation and characterization of copper bis[-(α-(hydroxyimino)benzyl)phosphonate]-water. Inorg Chem 1989;28(10):1928-1932.

(101) Ringel I, Bakshi O, Mellado W, Ramu A, Gibson D, Katzhendler J. N-Alkyl colchiceineamides: their inhibition of GTP or taxol-induced assembly of tubulin. Biochem Pharmacol 1988;37(12):2487-2489.

(102) Breuer E, Karaman R, Goldblum A, Gibson D, Leader H, Potter BVL, et al. α-Oxyiminophosphonates: Chemical and physical properties. Reactions, theoretical calculations, and x-ray crystal structures of (E) and (Z)-dimethyl α-hydroxyiminobenzylphosphonates. Journal of the Chemical Society, Perkin Transactions 1 1988(11):3047-3057.

(103) Breuer E, Karaman R, Gibson D, Leader H, Goldblum A. α-hydroxyiminophosphonic acids. New types of phosphorylating agents through monomeric metaphosphate. Journal of the Chemical Society, Chemical Communications 1988(7):504-506.

(104) Kitov S, Ben-Shoshan R, Ringel I, Gibson D, Katzhendler J. The effect of cis-platin analogues derived from aminoalkylaminoanthraquinones on DNA cleavage: an electron microscopy study. Eur J Med Chem 1988;23(4):381-383.

(105) Sherman SE, Gibson D, Lippard SJ, Wang AHJ. Crystal and Molecular Structure of cis-[Pt(NH3)2{d(pGpG)}], the Principal Adduct Formed by cis-Diamminedichloroplatinum(II) with DNA. J Am Chem Soc 1988;110(22):7368-7381.

(106) Villacorta GM, Gibson D, Williams ID, Whang E, Lippard SJ. Alkyne-Bridged Dicopper(I) Complexes of the Tropocoronand Macrocycles. Organometallics 1987;6(11):2426-2431.

(107) Gibson D, Lippard SJ. Synthesis and NMR Structural Studies of the Adduct of trans -Diamminedichloroplatinum(II) with the DNA Fragment d(GpCpG). Inorg Chem 1987;26(14):2275-2279.

(108) Gibson D, Lippard SJ. Preparation and Structural Characterization of a Novel Hexanuclear Complex of Platinum(II) with 2-Aminoethanethiolate. Inorg Chem 1986;25(2):219-222.

(109) Bino A, Gibson D. Tritungsten(IV) cluster compounds with hydroxo ligands. Preparation and structure of [W3O2(O2CCH3)6(H2O)(OH)2]·16H2O and [W3O2(O2CCH3)6(H2O)(OH)2]·KBr·15H2O. Inorg Chim Acta 1985;104(3):155-160.

(110) Shamir J, Luski S, Bino A, Cohen S, Gibson D. Tetrachloro-phosphonium salts of hexachloro antimonate and niobate and their solvates. Preparation and structure by vibrational spectroscopy and x-ray crystallography. Inorg Chim Acta 1985;104(2):91-97.

(111) Shamir J, Luski S, Bino A, Cohen S, Gibson D. Reactions of Phosphorus Pentachloride with Tin Tetrachloride. Tetrachlorophosphonium Salts with SnCl62-, Sn2Cl102-, and SnCl5- Anions: Preparation and Structure by Vibrational Spectra and X-ray Crystallography. Inorg Chem 1985;24(14):2301-2309.

(112) Bino A, Gibson D. Hydrogen oxide (H3O2) bridge formation in trinuclear metal cluster systems. The structure of [W3O2(O2CCH3)6(H2O)(H3O2)] NCS·H2O. Inorg Chim Acta 1985;101(1):L9.

(113) Benory E, Bino A, Gibson D, Cotton FA, Dori Z. Oxalato complexes of the trinuclear aquo ion of molybdenum(IV), [Mo3O4]4+. Inorg Chim Acta 1985;99(2):137-142.

(114) Sherman SE, Gibson D, Wang AH-, Lippard SJ. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2{d(pGpG)}]. Science 1985;230(4724):412-417.

(115) Villacorta GM, Gibson D, Williams ID, Lippard SJ. Dicopper(I) Tropocoronands: Synthesis, X-ray Crystal Structure, and Spectral Properties of Neutral Binuclear Copper(I) Complexes Bridged by Symmetrically Substituted Alkynes. J Am Chem Soc 1985;107(23):6732-6734.

(116) Feinstein-Jaffe I, Gibson D, Lippard SJ, Schrock RR, Spool A. A Molecule Containing the OWOWO Unit. Synthesis, Structure, and Spectroscopy of W2O3(CH2CMe3)6. J Am Chem Soc 1984;106(21):6305-6310.

(117) Bino A, Gibson D. The Hydrogen Oxide Bridging Ligand (H302-). 2. Effect of the Hydrogen Ion Concentration. Inorg Chem 1984;23(1):109-115.

(118) Bino A, Gibson D. Trinuclear Mo(IV) cluster ion with a propylidyne cap. Inorg Chim Acta 1982;65(C):L37-L38.

(119) Bino A, Gibson D. The Hydrogen Oxide Bridging Ligand (H3O2−). 1. Dimerization and Polymerization of Hydrolyzed Trinuclear Metal Cluster Ions. J Am Chem Soc 1982;104(16):4383-4388.

(120) Bino A, Gibson D. A New Bridging Ligand, the Hydrogen Oxide Ion (H302−). J Am Chem Soc 1981;103(22):6741-6742.

(121) Bino A, Gibson D. A New, Convenient, and Efficient Route to Dimolybdenum(II) Compounds from MoO3. J Am Chem Soc 1980;102(12):4277-4278.